Genmab — Oktober 2020
-
AMGEN: KYPROLIS
(carfilzomib) sales decreased 2% year-over-year driven by volume declines, as fewer new patients began treatment due to COVID-19. Early indications point to a strong launch of the new once-weekly KYPROLIS and DARZALEX (daratumumab) combination regimen that was approved by the U.S. Food and Drug Administration (FDA) in August. -
Efficacy and safety of weekly carfilzomib (70 mg/m2), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option: a cross-study comparison of the CANDOR and EQUULEUS studies https://www.tandfonline.com/doi/full/10.1080/10428194.2020.1832672
-
A global antiB cell strategy combining obinutuzumab and daratumumab in severe pediatric nephrotic syndrome https://link.springer.com/article/10.1007/s00467-020-04811-0
-
Novartis is also starting a new trial for people with relapsing MS who switch to Kesimpta from another anti-CD20 monoclonal antibody therapy; ie. Ocrevus https://clinicaltrials.gov/ct2/show/NCT04486716
-
In addition, Novartis is exploring other avenues for Kesimpta’s clinical development, including plans to test the medication in children with MS. https://multiplesclerosisnewstoday.com/news-posts/2020/09/10/new-and-ongoing-trials-evaluating-kesimpta-including-as-switch-therapy/ “We are not stopping research into Kesimpta,” he added. “Research continues with Kesimpta to help more patients know of its value.”
-
Sarclisa
was approved in March in the U.S. for the treatment of adults with relapsed refractory multiple myeloma (RRMM) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and in June by the European Commission in certain adults with RRMM. Third-quarter Sarclisa sales were €13 million of which €9 million was generated in the U.S. despite the challenging launch environment due to COVID-19. Sarclisa is now launched in the U.S., Austria, Japan, -
Thanks to @EL for pushing news feed today. The markets seems to appreciate the flow
-
@E L
-
Sr
y for the last 2 posts - originally regards to E L -
-
-
God morgen .-)
-
-
God morgen.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind